Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.
| Revenue (Most Recent Fiscal Year) | $1.00M |
| Net Income (Most Recent Fiscal Year) | $-59.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5968.50% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -170.99% |
| Return on Assets (Trailing 12 Months) | -64.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.97 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.39 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 53.15M |
| Free Float | 47.62M |
| Market Capitalization | $88.23M |
| Average Volume (Last 20 Days) | 0.15M |
| Beta (Past 60 Months) | 1.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |